Tailoring modifications of polysaccharides in Mycobacterium tuberculosis

结核分枝杆菌多糖的剪裁修饰

基本信息

  • 批准号:
    10387219
  • 负责人:
  • 金额:
    $ 51.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-17 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

Abstract The covalent modification of prokaryotic cell envelope glycans, namely lipopolysaccharide (LPS) and (lipo)teichoic acids, with discrete substituents such as sugars, amino acids, phosphates or acyl groups, is a well-known strategy used by Gram-negative and Gram-positive bacteria to modulate their cell surface properties, the way they interact with their environment, their resistance to biocides and host defenses, and pathogenicity. Although evidence exists that Mycobacterium tuberculosis (Mtb) similarly decorates its major cell envelope glycans, arabinogalactan (AG) and lipoarabinomannan (LAM), with various tailoring substituents, little is known of their biological significance. The discovery by our laboratories of the biosynthetic machineries responsible for the synthesis and transfer of these discrete motifs to AG and LAM, and the generation of the first Mtb knock-out mutants deficient in their biosynthesis have opened the way to studies aimed at understanding the function of these motifs in the physiology and immunopathogenesis of Mtb. We hypothesize that Mtb has evolved to modify its cell-envelope glycans with a distinct array of strategically placed substituents to promote its survival in the host environment. Accordingly, a multidisciplinary team of investigators with complementary expertise in mycobacterial cell envelope genetics and glycobiology, TB immunopathogenesis, and carbohydrate chemistry here proposes to investigate how simple (amino/thio)sugars or other charged groups strategically placed within the Mtb cell envelope landscape affect not only the physiology of this microorganism (Aim 1), but also the course of pulmonary infection, pathology and development of innate and adaptive immunity in infected C3HeB/FeJ mice (Aim 2), and the interactions of Mtb with host macrophages and dendritic cells thereby promoting survival within the host (Aim 3). Ultimately, these studies are expected to lead to significant new knowledge about the biological significance of understudied aspects of the unique cell wall of mycobacteria.
摘要 原核细胞包膜聚糖,即脂多糖(LPS)和 具有离散取代基如糖、氨基酸、磷酸酯或酰基的(脂)磷壁酸是一种脂族磷壁酸。 革兰氏阴性和革兰氏阳性细菌用来调节其细胞表面的众所周知的策略 特性,它们与环境相互作用的方式,它们对杀生物剂和宿主防御的抗性,以及 致病性尽管有证据表明结核分枝杆菌(Mtb)也以类似的方式修饰其主要结构, 细胞包膜聚糖,阿拉伯半乳聚糖(AG)和脂阿拉伯甘露聚糖(LAM),具有各种定制取代基, 人们对其生物学意义知之甚少。我们实验室发现的生物合成机制 负责合成并将这些离散的基序转移到AG和LAM,并产生 第一个在其生物合成中有缺陷的Mtb敲除突变体为旨在 了解这些基序在Mtb的生理学和免疫发病机制中的功能。我们 假设Mtb已经进化到用一系列不同的 策略性地放置取代基以促进其在宿主环境中的存活。因此 多学科研究团队,在分枝杆菌细胞包膜遗传学方面具有互补的专业知识 和糖生物学,结核病免疫发病机制,和碳水化合物化学在这里提出调查如何 简单(氨基/硫代)糖或其他带电基团策略性地放置在Mtb细胞包膜内 不仅影响该微生物的生理学(目的1),而且影响肺部感染的过程, 感染C3 HeB/FeJ小鼠的先天性和适应性免疫的病理学和发展(目的2),以及 Mtb与宿主巨噬细胞和树突状细胞的相互作用,从而促进宿主内的存活(Aim 3)。最终,这些研究有望导致有关生物学意义的重要新知识 分支杆菌独特细胞壁的未充分研究的方面。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mercedes Gonzalez-Juarrero其他文献

Mercedes Gonzalez-Juarrero的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mercedes Gonzalez-Juarrero', 18)}}的其他基金

Inhaled tigecycline therapy for pulmonary M. abscessus infections
吸入替加环素治疗肺部脓肿分枝杆菌感染
  • 批准号:
    10312329
  • 财政年份:
    2021
  • 资助金额:
    $ 51.17万
  • 项目类别:
Inhaled tigecycline therapy for pulmonary M. abscessus infections
吸入替加环素治疗肺部脓肿分枝杆菌感染
  • 批准号:
    10437923
  • 财政年份:
    2021
  • 资助金额:
    $ 51.17万
  • 项目类别:
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis
结核分枝杆菌多糖的剪裁修饰
  • 批准号:
    10490882
  • 财政年份:
    2021
  • 资助金额:
    $ 51.17万
  • 项目类别:
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis
结核分枝杆菌多糖的剪裁修饰
  • 批准号:
    10685409
  • 财政年份:
    2021
  • 资助金额:
    $ 51.17万
  • 项目类别:
Inhaled tigecycline therapy for pulmonary M. abscessus infections
吸入替加环素治疗肺部脓肿分枝杆菌感染
  • 批准号:
    10626051
  • 财政年份:
    2021
  • 资助金额:
    $ 51.17万
  • 项目类别:
Vectra Polaris microscope imaging system
Vectra Polaris 显微镜成像系统
  • 批准号:
    10175807
  • 财政年份:
    2021
  • 资助金额:
    $ 51.17万
  • 项目类别:
Minipigs as animal model for infant TB and vaccine efficacy
小型猪作为婴儿结核病和疫苗功效的动物模型
  • 批准号:
    8810222
  • 财政年份:
    2014
  • 资助金额:
    $ 51.17万
  • 项目类别:
siRNA-nanoparticles host targeted immunotherapy for tuberculosis
siRNA 纳米颗粒作为结核病靶向免疫疗法的宿主
  • 批准号:
    8638299
  • 财政年份:
    2014
  • 资助金额:
    $ 51.17万
  • 项目类别:
Minipigs as animal model for infant TB and vaccine efficacy
小型猪作为婴儿结核病和疫苗功效的动物模型
  • 批准号:
    8684285
  • 财政年份:
    2014
  • 资助金额:
    $ 51.17万
  • 项目类别:
Host targeted immunotherapy for TB treatment
结核病治疗的宿主靶向免疫疗法
  • 批准号:
    8487363
  • 财政年份:
    2012
  • 资助金额:
    $ 51.17万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 51.17万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.17万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 51.17万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.17万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 51.17万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 51.17万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.17万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 51.17万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 51.17万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.17万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了